{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910459964503321"]
[null,null,"Autore",null,"Eyjolfsson Reynir"]
[null,null,"Titolo",null,"Design and manufacture of pharmaceutical tablets / / Reynir Eyjolfsson"]
[null,null,"Pubbl/distr/stampa",null,"London, England : , : AP, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"0-12-802187-X"]
[null,null,"Descrizione fisica",null,"1 online resource (68 p.)"]
[null,null,"Disciplina",null,"615.1"]
[null,null,"Soggetti",null,"Drugs - Dosage forms"]
[{"$nulls":4},"Pharmaceutical industry"]
[{"$nulls":4},"Tablets (Medicine)"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Cover; Title Page; Copyright Page; Dedication; Contents; Preface; Abbreviations; Chapter One - Introduction; 1.1 - General considerations; 1.2 - Particle sizes; 1.3 - Excipients; 1.3.1 - Ac-Di-Sol SD-711; 1.3.2 - Aerosil 200; 1.3.3 - Avicel PH-102; 1.3.4 - Compactrol; 1.3.5 - Corn starch; 1.3.6 - Di-Tab; 1.3.7 - Eudragit RS PO; 1.3.8 - Magnesium stearate 5712; 1.3.9 - Mannitol 60; 1.3.10 - Methocel K4M Premium; 1.3.11 - Methocel K100M Premium; 1.3.12 - Methocel K100LV Premium; 1.3.13 - Pharmatose 150M; 1.3.14 - Polyplasdone XL-10; 1.3.15 - Povidone; 1.3.16 - Primojel; 1.3.17 - Pruv"]
[{"$nulls":4},"1.3.18 - Sodium bicarbonate1.3.19 - Starch 1500; 1.3.20 - Stearic acid 2236; 1.3.21 - Sterotex K; 1.3.22 - Tablettose 80; 1.3.23 - Talc; 1.4 - Equipment; 1.5 - Mixing of pharmaceutical powders; 1.6 - Design of experiments; 1.6.1 - Introduction to statistical design of experiments - the two-level factorial; 1.6.1.1 - Introduction; 1.6.1.2 - Designed experiments; 1.6.1.3 - Basic considerations; 1.6.1.4 - Two-level factorials; 1.6.1.5 - Two-level fractional factorials; 1.6.2 - Response surface methodology (RSM); 1.6.2.1 - Introduction; 1.6.2.2 - RSM and a sieving process variable study"]
[{"$nulls":4},"1.6.2.3 - RSM investigation of the properties of a three-component tablet formulationReferences; Chapter two - Conventional-Release (CR) Tablets; 2.1 - Low-dose tablet by direct compression (DC); 2.1.1 - "]
[{"$nulls":4},"Properties of active pharmaceutical ingredient (API); 2.1.2 - Design; 2.1.3 - Manufacturing method; 2.1.4 - Remarks; 2.2 - High-dose tablet by direct compression; 2.2.1 - Properties of active pharmaceutical ingredient; 2.2.2 - Design; 2.2.3 - Manufacturing method; 2.2.4 - Remarks; 2.3 - Low-solubility API, low-dose tablet by wet granulation (WG)"]
[{"$nulls":4},"2.3.1 - Properties of active pharmaceutical ingredient2.3.2 - Design; 2.3.3 - Manufacturing method; 2.3.4 - Remarks; 2.4 - Soluble API, low-dose tablet by wet granulation; 2.4.1 - Properties of active pharmaceutical ingredient; 2.4.2 - Design; 2.4.3 - Manufacturing method; 2.4.4 - Remarks; 2.5 - Low-solubility API, high-dose tablet by wet granulation; 2.5.1 - Properties of active pharmaceutical ingredient; 2.5.2 - Design; 2.5.3 - Manufacturing method; 2.5.4 - Remarks; 2.6 - Soluble API, high-dose tablet by wet granulation; 2.6.1 - Properties of active pharmaceutical ingredient; 2.6.2 - Design"]
[{"$nulls":4},"2.6.3 - Manufacturing method2.6.4 - Remarks; References; Chapter three - Slow-Release (SR) Tablets; 3.1 - Slow-release tablet using a lipophilic release control agent; 3.1.1 - Properties of active pharmaceutical ingredient (API); 3.1.2 - Design; 3.1.3 - Manufacturing method; 3.1.4 - Remarks; 3.2 - Slow-release tablet using Eudragit and Methocel as release control agents; 3.2.1 - Properties of active pharmaceutical ingredient; 3.2.2 - Design; 3.2.3 - Manufacturing method; 3.2.4 - Remarks; 3.3 - Slow-release tablet using a mixture of Methocels as release control agent"]
[{"$nulls":4},"3.3.1 - Properties of active pharmaceutical ingredient"]
[null,null,null,"Sommario/riassunto","Design and Manufacture of Pharmaceutical Tablets offers real world solutions and outcomes of formulation and processing challenges of pharmaceutical tablets.  This book includes numerous practical examples related to actual formulations that have been validated and marketed and covers important data in the areas of stability, dissolution, bioavailibity and processing.  It provides important background and theoretical information on design and manufacturing and includes a full section dedicated to design experimental methodology and statistics.  In addition, this book offers a a general discuss"]